TP53 and urinary bladder cancer: Additionally, the frequencies of Pro homozygosity was higher in the patients than in the controls among all three sample sets (sample set 1, 20.93 vs. 17.33%; sample set 2, 24.47 vs. 18.31%, merged samples, 22.42 vs. 17.57%); thereby, the genotype Pro/Pro was viewed as risk allele, multivariate logistic regression was preceded to investigate the possible effect of p53 codon 72 polymorphism in bladder cancer incidence with age and gender adjusted.